Metra M, Dei Cas L
Cattedra di Cardiologia, Università di Brescia, Italy.
Clin Cardiol. 1995 Mar;18(3 Suppl I):I22-31. doi: 10.1002/clc.4960181307.
Ibopamine, the most widely studied dopaminergic drug for the treatment of chronic heart failure, appears to have beneficial hemodynamic, renal, and neurohormonal effects in this setting. Angiotension-converting enzyme (ACE) inhibitors have become the recommended standard treatment for chronic heart failure; however, some patients may benefit from additional drugs to improve their symptoms and functional capacity. Ibopamine may be effective as an additive drug for patients with chronic heart failure. It is also possible that ibopamine will improve survival in these patients. Large-scale trials are needed to assess the effects on morbidity and mortality when ibopamine is added to ACE inhibitors, diuretics, and possibly digitalis.
异波帕胺是治疗慢性心力衰竭研究最为广泛的多巴胺能药物，在这种情况下似乎具有有益的血流动力学、肾脏和神经激素效应。血管紧张素转换酶（ACE）抑制剂已成为慢性心力衰竭的推荐标准治疗药物；然而，一些患者可能从其他药物中获益，以改善其症状和功能能力。异波帕胺作为慢性心力衰竭患者的辅助药物可能有效。异波帕胺也有可能改善这些患者的生存率。需要进行大规模试验来评估将异波帕胺添加到ACE抑制剂、利尿剂以及可能的洋地黄类药物中对发病率和死亡率的影响。
